Mridu Gulati, MD, MPH

Mridu Gulati, MD, MPH
Assistant Professor of Medicine
Associate Director, Yale-ILD
Yale School of Medicine

Play

CME/CE Information

Activity Title Patient Monitoring, Management, and the Coordination of Care
Topic Idiopathic Pulmonary Fibrosis
Accreditation Type AMA PRA Category 1 Credits™
Release Date December 2014
Expiration Date December 31, 2015
Estimated Time to Complete Activity 15 minutes

LEARNING OBJECTIVES

Upon completion of the activity, participants should be able to:

  • Formulate a plan for communication with patients and families on all aspects of care
  • Identify opportunities for referral as part of the multidisciplinary IPF management plan

ACTIVITY FACULTY

Mridu Gulati, MD, MPH
Assistant Professor of Medicine
Associate Director, Yale-ILD
Yale School of Medicine

METHOD OF PARTICIPATION / HOW TO RECEIVE CREDIT

  1. There are no fees for participating in and receiving credit for this activity.
  2. Review the activity objectives and CME/CE information.
  3. Complete the CME/CE activity.
  4. Complete the posttest. A score of at least 75% is required to successfully complete this activity. The participant may take the test until successfully passed.
  5. Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice, the perception of commercial bias, and whether or not the objectives were met.
  6. Your CME/CE certificate will be available for download.

CLICK HERE TO VIEW TECHNICAL REQUIREMENTS


SPONSOR

This activity is sponsored by The France Foundation.


TARGET AUDIENCE

This activity is intended for physicians, surgeons, critical care clinicians, advanced practice nurses, and other health care professionals involved in the diagnosis and management of patients with IPF.

STATEMENT OF NEED

Idiopathic pulmonary fibrosis (IPF) is characterized by progressive worsening of dyspnea and lung function and is associated with a poor prognosis. Today, median survival time from diagnosis of IPF is two to five years. In 2011 an international committee of the American Thoracic Society (ATS) and European Respiratory Society (ERS) published updated guidelines for the diagnosis and management of patients with IPF. These are still challenges for health care providers who treat patients with IPF. These include acute exacerbations and comorbid conditions commonly seen in patients with IPF. In October 2014 the FDA approved two new drugs for the treatment of IPF. These therapies transform the management of IPF and present new options for practitioners and patients.

ACCREDITATION STATEMENT

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Physicians
The France Foundation designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DISCLOSURES

It is the policy of The France Foundation to ensure balance, independence, objectivity, and scientific rigor in all its sponsored educational activities. All faculty, activity planners, content reviewers, and staff participating in this activity have disclosed to the participants any significant financial interest or other relationship with manufacturer(s) of any commercial product(s)/device(s) and/or provider(s) of commercial services included in this educational activity. The intent of this disclosure is not to prevent a person with a relevant financial or other relationship from participating in the activity, but rather to provide participants with information on which they can base their own judgments. The France Foundation has identified and resolved any and all conflicts of interest prior to the release of this activity.

Activity Staff Disclosures

The planners, reviewers, editors, staff, CME committee, or other members at The France Foundation who control content have no relevant financial relationships to disclose.

Faculty Disclosures

The following faculty has indicated she has relationships with industry to disclose relative to the content of this CME activity:

  • Mridu Gulati, MD, has received grants/research support from the National Institutes of Health (NIH), and served as a consultant for Boehringer Ingelheim and InterMune.

UNAPPROVED USE DISCLOSURE

The France Foundation requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

COMMERCIAL SUPPORT ACKNOWLEDGMENT

This activity is supported by an educational grant from Intermune.

DISCLAIMER

The France Foundation presents this information for educational purposes only. The content is provided solely by faculty who have been selected because of recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation and Bayer Global assume no liability for the information herein.

COPYRIGHT INFORMATION

Copyright © 2014 The France Foundation. Any unauthorized use of any materials on the site may violate copyright, trademark, and other laws. You may view, copy, and download information or software ("Materials") found on the Site subject to the following terms, conditions, and exceptions:

  • The materials are to be used solely for personal, noncommercial, informational and educational purposes. The materials are not to be modified. They are to be distributed in the format provided with the source clearly identified. The copyright information or other proprietary notices may not be removed, changed, or altered.
  • Materials may not be published, uploaded, posted, transmitted (other than as set forth herein), without The France Foundation's prior written permission.

PRIVACY POLICY

The France Foundation protects the privacy of personal and other information regarding participants and educational collaborators. The France Foundation will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.

The France Foundation maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.

Additional information regarding The France Foundation's Privacy Policy can be viewed at http://www.francefoundation.com/privacy.

CONTACT INFORMATION

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or This email address is being protected from spambots. You need JavaScript enabled to view it..

Play



Access other Therapeutic Areas: